Cargando…
Transferrin-Conjugated PLGA Nanoparticles for Co-Delivery of Temozolomide and Bortezomib to Glioblastoma Cells
[Image: see text] Glioblastoma (GBM) represents almost half of primary brain tumors, and its standard treatment with the alkylating agent temozolomide (TMZ) is not curative. Treatment failure is partially related to intrinsic resistance mechanisms mediated by the O6-methylguanine-DNA methyltransfera...
Autores principales: | Ramalho, Maria João, Torres, Inês David, Loureiro, Joana Angélica, Lima, Jorge, Pereira, Maria Carmo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10426337/ https://www.ncbi.nlm.nih.gov/pubmed/37588263 http://dx.doi.org/10.1021/acsanm.3c02122 |
Ejemplares similares
-
Factorial Design as a Tool for the Optimization of PLGA Nanoparticles for the Co-Delivery of Temozolomide and O6-Benzylguanine
por: Ramalho, Maria João, et al.
Publicado: (2019) -
Transferrin Receptor-Targeted Nanocarriers: Overcoming Barriers to Treat Glioblastoma
por: Ramalho, Maria João, et al.
Publicado: (2022) -
Interaction of Bortezomib with Cell Membranes Regulates Its Toxicity and Resistance to Therapy
por: Ramalho, Maria João, et al.
Publicado: (2022) -
PLGA Based Drug Carrier and Pharmaceutical Applications: The Most Recent Advances
por: Loureiro, Joana Angélica, et al.
Publicado: (2020) -
PLGA nanoparticles as a platform for vitamin D-based cancer therapy
por: Ramalho, Maria J, et al.
Publicado: (2015)